Vertex Pharmaceuticals (VRTX) Leerink Global Healthcare Conference 2026 summary

Strategic goals and financial outlook

• Four primary goals for 2026: extend CF leadership, accelerate commercial diversification (JOURNAVX, CASGEVY), advance a broad pipeline (five Phase 3s), and deliver consistent financial results with 8%-9% revenue growth guidance ($12.95B-$13.1B).

• At least $500M in 2026 revenue expected from non-CF products, marking significant acceleration over 2025.

• Operating margins maintained in the low-to-mid 40% range despite ongoing investments in pipeline and commercial infrastructure.

• Multiple multibillion-dollar franchises anticipated in the next two to five years, supporting commercial diversification.

• JOURNAVX prescriptions expected to triple in 2026, with improved revenue conversion due to expanded coverage.

Pipeline and clinical data highlights

• Five Phase 3 trials ongoing in AMKD, type 1 diabetes, DPN, and two for POVI (PMN and IgAN).

• POVI in IgAN showed statistically significant efficacy: 52% reduction in UPCR at 36 weeks, 77% reduction in Gd-IgA1 antibodies, and 85% hematuria resolution.

• Safety profile for POVI was strong: no SAEs, deaths, or discontinuations due to infection; serious infection rates were low and similar to placebo.

• Regulatory filing for POVI in IgAN accelerated to end of the current month, aiming for near-term commercial launch.

• Additional data for POVI to be disclosed at future congresses and upon trial completion; final study runs to 104 weeks with interim at 36 weeks.

Product and franchise updates

• ALYFTREK continues to see patient transitions from TRIKAFTA in the US and Europe, with positive feedback from physicians and patients.

• JOURNAVX Phase 4 data showed over 90% patient satisfaction and 90% opioid-free recovery in aesthetic/reconstructive surgeries; similar strong results in arthroscopic/laparoscopic procedures.

• Over 200 million lives now covered for JOURNAVX, with ongoing efforts to secure Medicare coverage and continued patient support programs.

• CASGEVY saw over 300 patients starting treatment in 2025, with continued progress and some quarterly volatility due to patient scheduling preferences.

• VX-828 (CF franchise) Phase 1b data expected in the second half of this year, aiming to surpass ALYFTREK and TRIKAFTA efficacy.